Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors
- 28 March 2012
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 158 (3), 386-392
- https://doi.org/10.1016/j.jconrel.2011.12.001
Abstract
No abstract availableFunding Information
- NIH (R21 CA135130)
- AAPS New Investigator Award
- AAPS Travel Award
- Lilly Endowment, Inc.
This publication has 54 references indexed in Scilit:
- Recent progress in the diagnosis and treatment of ovarian cancerCA: A Cancer Journal for Clinicians, 2011
- 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in miceBMC Cancer, 2010
- The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis modelInvestigational New Drugs, 2010
- Drug Delivery Systems for Intraperitoneal TherapyPharmaceutical Research, 2010
- Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian CancerThe Journal of pharmacology and experimental therapeutics, 2008
- Polymers in the prevention of peritoneal adhesionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- In Situ Cross-linkable Hyaluronan Hydrogels Containing Polymeric Nanoparticles for Preventing Postsurgical AdhesionsAnnals of Surgery, 2007
- Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal PaclitaxelPharmaceutical Research, 2007
- In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit modelBiomaterials, 2006
- Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulationEuropean Journal of Cancer, 2001